Vaccine Congress Washington Agenda

 

 

World Vaccine Congress Washington is a multi-faceted conference experience with over 300 industry leading speaker, 10 conferences, 8 workshops, 100+ exhibitors providing the most exciting vaccine event on the planet. It is carefully curated by an experienced team who are plugged into a global network. Our presenters are disruptors and visionary industry leaders from the biopharma industry. They are selected for their relevance, dynamism and insight. 

 

BOOK BY FEB 7 & SAVE

 

  

Washington D.C., 6 - 9 April 2020

Schedule

Create your personal agenda –check the favourite icon

Apr 708:20
Conference pass

Chair's opening remarks

Keynotes
Gregory Poland, Director Of Mayo Vaccine Research Group, Mayo Clinic
Apr 708:30
Conference pass

Strengthening the effectiveness of national, state & local efforts to improve the vaccination uptake

Keynotes
  • How do we deal with the measles outbreak?
Apr 708:45
Conference pass

Vaccinology for the 21st century in addressing emerging infectious diseases

Keynotes
Tony Fauci, Director, NIAID, NIH
Apr 709:15
Conference pass

Deploying and implementing vaccines during an outbreak: EBOLA

Keynotes
  • Global strategy, alignment ad local partnerships between all stakeholders
  • Overcoming challenges in DRC for successful implementation and rapid response
  • Lessons learned with international deployment in outbreak regions
Moderator: Inger Damon, Director, Division Of High Consequence Pathogens And Pathology, Centers for Disease Control and Prevention
Richard Hatchett, Chief Executive Officer, CEPI
Paul Stoffels, Chief Scientific Officer, Johnson & Johnson
Kate O'Brien, Director, World Health Organisation
Jean-Jacques Muyembe-Tamfum, General Director, Democratic Republic of Congo
Tony Fauci, Director, NIAID, NIH
Apr 711:40
Conference pass

INTERACTIVE ROUNDTABLES

Keynotes
Analytical Issues Impacting Quality in Vaccine Development
Artificial intelligence -adopting cognitive computing across the PV landscape
Best practices for site partnerships with CRO/PHARMA for vaccine trials
William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC
CEPI 2020 funding calls
Challenges for development of GMO vaccines
Marc Hoffman, Chief Medical Officer, Celerion
Changing landscape of real-world evidence and its impact on clinical research – uncovering lab & clinical adverse events
Changing scenario of veterinary vaccine market in the developing world
Choke points in vaccine study start up -- An investigator’s view
Developing more effective vaccines for emerging/re-emerging pandemic threats
Dr James Cummings, President, ICON Government & Public Health Solutions
Development of novel predictive algorithms for patient selection
Eyes wide open: investigation perspectives on conducting vaccine trials
Dr Olutola Adetona, Principal Investigator, Tekton Research
How to onboard new digital technologies for absolute quantification of AAV vectors as part of scalable purification process for gene therapies
Human Challenge studies: Dengue, Zika, Ebola: How far can we go?
Bruno Speder, Head Of Clinical Regulatory Affairs, SGS Life Sciences
Immune Profiling - capturing the complexity of immune responses to vaccines and infections
Is vaccine hesitancy affecting recruitment for clinical trials?
Key Elements of building a successful partnership between sponsor and CRO
New qualitative analytical technology replacing antiquated plaque and TCID50 assays
Dr Gray Heppner, Chief Medical Officer And Managing Partner, Crozet BioPharma LLC
Sean Hart, Chief Executive Officer, LumaCyte
Oncology – applying precision medicine and informatics to find the best treatment option for each patient
Overcoming obstacles to improve cold chain management of biologics
Pediatric vaccine trials – Recruitment and retention
Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies?
Seasonal vaccine studies: Critical success factors
Cynthia Dukes, Vice President, Drug Development, Rare Disease, ICON plc
Using Government Funding to Support Your Vaccine Development Program; What is “non-diluted” funding? How do you receive it?
Russ Coleman, Vice President, Rho World
Vaccine, Vaccination, and Immunization Law
Brian Abramson, Bloomberg Law
When limited patient resources meet unlimited immunotherapy combinations—the strategies to develop clinical IO agents in platform studies
Apr 714:30
Conference pass

Chair's opening remarks

One Health
Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Apr 714:30
Conference pass

Global health challenges: How far are we from eliminating treatable infectious diseases?

Keynotes
  • Bridging multiple technologies for holistic treatment strategies
  • HIV, TB, malaria, Cholera, NTDs
Dr Peter Hotez, Dean, National School Of Tropical Medicine, Director, Texas Children?S Hospital Center, Baylor College of Medicine
Dr Ann Ginsberg, Senior Technical Advisor, International Aids Vaccine Initiative
Thomas Breuer, Senior Vice President, Chief Medical Officer, GSK Vaccines
Daria Hazuda, Vice President, Therapeutic Area, Head Of Infectious Disease And Chief Scientific Officer, Merck
Apr 714:35
Conference pass

AMR: What’s the strategy?

One Health
  • Insight on how the human health and veterinary medicine industry is contributing to the fight against AMR
Mahesh Kumar, Senior Vice President, Global Biologics Research, Zoetis
Jesse Sevcik, Director, Elanco Animal Health
Apr 715:20
Conference pass

The importance of a One Health approach to biodefense and biosecurity

One Health
  • Overview of current threats
  • Insight from US & European countries: How do our governments prepare for outbreaks?
  • How do we ensure rapid manufacturing capabilities for dealing with outbreaks?
Lisa Conti, Co-Founder, One Health Initiative
Dorothy Peprah, Senior Global Health Security Agenda Advisor, United States Agency For International Development
Prof Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz), University of Veterinary Medicine Hannover
Deborah Whitmer, Chief Of Staff, U.S. Army Medical Research and Development Command
Michael Angelastro, Project Officer, U.S. Department of Health & Human Services
Apr 715:20
Conference pass

How can we be better prepared for vaccine launches? The future of the vaccine business from the executives

Keynotes
  • Considerations of an early engagement plan and ethics beyond vaccine development
  • Best practices and lessons learned from emerging infectious diseases and international settings
Dr John Markels, President, Merck Vaccines
Thomas Breuer, Senior Vice President, Chief Medical Officer, GSK Vaccines
Paul Stoffels, Chief Scientific Officer, Johnson & Johnson
Apr 716:50
Conference pass

Elevating clinical science and design of vaccines for the purpose of control and eradication: African Swine Fever

One Health
  • What can we learn from current ASF outbreaks?
  • What is the economic analysis? What’s the impact for the food production for people?
  • Implementing lessons learned for future response and preparedness
Andriy Rozstalnyy, Animal Production and Health Officer, F.A.O
Jee Yong Park, Chargé de Mission, Oie World Organisation For Animal Health
Sandra Blome, Deputy Head, Friedrich-Loeffler-Institut
Apr 716:50
Conference pass

How are our government agencies responding to public health emergencies?

Keynotes
  • What are the unique strengths of each agency?
  • Are we working collaboratively enough to effectively manage public health outbreaks and national security in a meaningful way?
  • Are there ways to improve synergistic vaccine research efforts?
Moderator: Eric Lombardini, Commander, U.S. Army and Air Force Exchange H.Q. Europe and S.W. Asia
Col Deydre Teyhen, Dtp, Phd, Ocs, Commander, Walter Reed Army Institute Of Research
Tammy Beckham, Director, Office of Infectious Disease and HIV/AIDS Policy, NVPO, OASH, OS, HHS
Tammy Beckham, Director, Office of Infectious Disease and HIV/AIDS Policy, NVPO, OASH, OS, HHS
Apr 717:50
Conference pass

Influenza: Navigating viruses at the human–animal interface

One Health
  • Influenza surveillance and risk assessment
  • Advances towards a universal flu vaccine- human health now getting to trials, what about vet? How can we collaborate better?
Prof Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz), University of Veterinary Medicine Hannover
Apr 717:50
Conference pass

Real use of next generation approaches into new vaccines: Role of human mABs for discovery, therapy, and vaccine acceleration

Keynotes
  • Exploring new non-traditional vaccine technologies and progression from passive immunity
  • Using mAbs to accelerate vaccine development by anticipating some of the key biological and regulatory questions
  • Use of adjuvants and safety
Dr Gary Nabel, Chief Scientific Officer And Senior Vice President Head, North America R&D Hub, Sanofi Pasteur
Sanjay Phogat, Vice President R&D, Head Dpu, Italy, GSK
Ennio De Gregorio, Lab Head of Bio Analytics Research & Development, GlaxoSmithKline
Apr 718:15
Conference pass

Current status of rift valley fever vaccine development

One Health
  • Challenges and strategies for developing efficacious rift valley fever vaccines
John Wyckoff, Director, Colorado State University

Create your personal agenda –check the favourite icon

Apr 809:00
Conference pass

Chair’s opening remarks

Veterinary
Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Apr 809:00
Conference pass

Chair’s opening remarks

Vaccine Safety
Kathryn Edwards, Pediatrics Chair And Pediatrics Professor, Vanderbilt University
Apr 809:10
Conference pass

RNA frameshift errors provide new product opportunities against cancer

Immune Profiling
Apr 809:10
Conference pass

Update on approaches to the development of clinical combination therapies

Cancer & Immunotherapy
  • What are the fundamental principles of combination science?
  • Huge amounts of data have been generated from combination studies, how do you analyze these?
Apr 809:10
Conference pass

Zika vaccine update

Emerging and Infectious
Rosalind Hollingsworth, AVP Global Medical Expert Lead, Influenza, GMA, Sanofi Pasteur
Apr 809:10
Conference pass

Clinical trials of the future

Clinical Development
  • Use of real-world evidence for vaccine efficacy
  • How to get information from the field to a database
  • Regulatory perspective in new development areas
Moderator: William Gruber, Senior Vice President, Pfizer Vaccine Clinical Research, Pfizer
Kathleen Thompson-Culkin, Head, GlaxoSmithKline
Apr 809:10
Conference pass

How to teach an old dog new tricks: Application of an ageing approach to life cycle management of a vaccine

Bioprocess & Manufacture
Dr Malte Meppen, Director, Head Of Drug Product R&D (Italy), GSK
Apr 809:10
Conference pass

Panel: The Future of the Animal Health Business

Veterinary
  • Discussing the emerging trends in animal health & biologics (companion and production animals)
  • The emergence of human health technologies in the animal health space; Are these technologies too expensive to implement in animal health?
  • The importance of establishing strong collaboration/partnerships for advancing animal health innovation
  • What about emerging markets? - Finding success in Latin America, China & India etc.
Mahesh Kumar, Senior Vice President, Global Biologics Research, Zoetis
Apr 809:10
Conference pass

Give It Your Best Shot: Achieve success by leveraging federal labs as technology development and commercialization partners

Partnerships
Apr 809:10
Conference pass

Panel: Mandatory vaccination policies around the world, are they working?

Vaccine Safety
  • What has been the impact of the introduction of mandatory vaccination and other policies globally?
    • Has it had a positive impact overall or has it worsened polarization?
  • What have been the most successful strategies for communication?
  • Medical and religious exemptions
  • What is the relationship between the forcefulness of a policy and its impact on the rate of vaccination?
  • Using big data to analyze the spread of misinformation?
Daniel Salmon, Professor Global Disease Epidemiology And Control; Director, Institute For Vaccine Safety, Johns Hopkins Bloomberg School of Public Health
Alberto E Tozzi, Managing Director, Ospedale Pediatrico Bambino Gesu
Apr 809:10
Conference pass

What are the major causes of supply chain shortages?

Supply & Logistics
Bill Mcgillian, Associate Engineering Director, Merck
Apr 809:40
Conference pass

Immune responses to malaria infection and immunization

Immune Profiling
Ken Stuart, Founder, Center For Infectious Disease Research
Apr 809:40
Conference pass

Panel: Targeted approaches to combinations, what’s working?

Cancer & Immunotherapy
  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?
Apr 809:40
Conference pass

GSK’s RSV vaccine

Respiratory
Ilse Dieussaert, Director And Head, GlaxoSmithKline Vaccines
Apr 809:40
Conference pass

Interactive panel: Unique rapid production opportunities and challenges that face RNA delivery and manufacture

Bioprocess & Manufacture
  • Why and where will it make a difference?
  • How is it difference to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
Apr 810:10
Conference pass

Characterizing differences in immune responses of different age populations and using this information to build next generation vaccines

Immune Profiling
Albert Shaw, Professor of Medicine (Infectious Diseases), Yale University
Apr 810:10
Conference pass

Co-development of an RSV prophylactic program

Respiratory
Rosalind Hollingsworth, AVP Global Medical Expert Lead, Influenza, GMA, Sanofi Pasteur
Apr 810:10
Conference pass

New trial data from Malaria

Emerging and Infectious
Apr 810:10
Conference pass

When preparation meets opportunity: Reducing the odds of failure in late phase

Clinical Development
Apr 810:10
Conference pass

Zoetis’ bench to market experience: Monoclonal antibodies for companion animals

Veterinary
Andy Hillier, Medical Lead Dermatology And Allergy, Veterinary Specialty Operations, Zoetis
Apr 810:10
Conference pass

Does digital media provide any meaningful value for informing vaccine safety?

Vaccine Safety
Apr 810:10
Conference pass

End-to-end supply; examples of deviations and solutions to overcome them

Supply & Logistics
Bill Mcgillian, Associate Engineering Director, Merck
Apr 811:40
Conference pass

Precision Vaccines: Using systems biology to inform development of vaccines for vulnerable populations

Immune Profiling
Apr 811:40
Conference pass

What have we learnt from the first neoantigen prediction results from the TESLA project

Cancer & Immunotherapy
Apr 811:40
Conference pass

Results from the Phase 2 trial of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults Assessing Immune and Safety Using a Prime or Prime+Boost Schedule

Respiratory
Dr Cheryl Keech, Executive Medical Director, PPD
Keith Rubin, Chief Executive Officer, ILiAD Biotechnologies, LLC
Apr 811:40
Conference pass

New correlate and challenge data from Janssen’s Malaria vaccine

Emerging and Infectious
Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Vaccines & Prevention B.V.
Apr 811:40
Conference pass

Got informatics? Practical applications of informatics in modern vaccine trial design

Clinical Development
Apr 811:40
Conference pass

Improving global availability and affordability of key vaccines

Bioprocess & Manufacture
Chris Yallop, Chief Operations And Scientific Officer, Batavia Biosciences
Apr 811:40
Conference pass

Novel vaccine technique to target multiple poultry diseases using CRISPR/Cas9 system

Veterinary
Venugopal Nair, Head, The Pirbright Institute
Apr 811:40
Conference pass

Showcase 1 - A synthetic carbohydrate-based conjugate vaccine against Shigella

Partnerships
Christiane Gerke, Head Of Vaccine Programs, Institut Pasteur
Apr 811:40
Conference pass

Joint presentation: Improving the ways that we engage with individuals around immunization: development and implementation of new and existing tools

Vaccine Safety
Apr 811:40
Conference pass

Overcoming logistical challenges for global clinical trials - Title TBC

Supply & Logistics
Paddy Hanlon, Vice President, Commercial Operations, Marken
Apr 812:10
Conference pass

Omics studies in vaccine trials to deduce markers & mechanisms of protection for effective immunity

Immune Profiling
  • Analysis of differences in response between resource rich and resource poor areas; what can we learn from this?
Patrick Duffy, Chief Of Pathogenesis And Immunity Section, National Institutes of Health
Apr 812:10
Conference pass

Computational methods to confirm and prioritize neoantigen candidates

Cancer & Immunotherapy
Apr 812:10
Conference pass

Best Practices in Vaccine Study Execution

Clinical Development
Cynthia Dukes, Vice President, Drug Development, Rare Disease, ICON plc
Apr 812:10
Conference pass

CanSino’s adenovirus-based viral vector technology platform and its applications in vaccine development

Bioprocess & Manufacture
Apr 812:25
Conference pass

Large animal challenge models for assessment of human and veterinary negative strand virus recombinant vaccines

Veterinary
Louise Cosby, Head Of Virology, Agri-Food and Biosciences Institute
Apr 812:40
Conference pass

Immunosenescence and influenza vaccination in older individuals

Immune Profiling
Apr 812:40
Conference pass

Accelerating vaccine process development and increasing productivity with single use intensified processing and predictive process control

Bioprocess & Manufacture
Jean-Marc Cappia, Head Of Vaccines Segment, Sartorius Stedim Biotech GmbH
Apr 812:40
Conference pass

Novel industrially proven hyper productive C1 expression system for biotherapeutics such as vaccines & antibodies

Veterinary
Mark Emalfarb, President and Chief Executive Officer, Dyadic International Inc
Apr 812:40
Conference pass

Public perceptions of vaccines; a media perspective

Vaccine Safety
Lena H Sun, National Reporter, The Washington Post Company
Apr 812:55
Conference pass

Novel viral vaccine vector platform for respiratory and emerging viruses

Emerging and Infectious
Ultan Power, Professor of Molecular Virology, Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast
Apr 814:40
Conference pass

Immune profiling and biomarker-based approaches during clinical development of novel vaccines: Are we there yet?

Immune Profiling
Rolando Pajon, Director, Moderna Inc.
Apr 814:40
Conference pass

The impact of a universal influenza vaccine

Respiratory
Meagan Fitzpatrick, Assistant Professor Of The Center For Vaccine Development And Global Health, University of Maryland
Apr 814:40
Conference pass

Universal influenza vaccine development: Diversity matters & an update on RSV

Respiratory
Barney Graham, Deputy Director Of Vaccine Research Center, National Institute of Health - NIAID
Apr 814:40
Conference pass

DNA-launched live-attenuated flavivirus vaccines

Emerging and Infectious
Pei-Yong Shi, Kempner Professor Of Human Genetics, University of Texas Medical Branch
Apr 814:40
Conference pass

The advantages of conducting early phase clinical trials in Australia

Clinical Development
Angela Luttick, EVP, Business Development, 360biolabs Pty Ltd
Cameron Johnson, Chief Executive Officer, Nucleus Network
Matt Clacy, Chief Commercial Officer, Paratus Clinical
Amelia Beshara, Senior Business Development Manager, Clinical Network Services (CNS) Pty Ltd
Apr 814:40
Conference pass

Increasing production of live viral vaccines and vectors with novel bioreactor technologies

Bioprocess & Manufacture
  • A historical perspective on adherent and non-adherent live-virus vaccine production and how recent advances in bioreactors allow for greater productivity and reduced costs per dose
Apr 814:40
Conference pass

Panel: Unravelling dengue vaccine safety concerns: To what extend could they have been predicted?

Vaccine Safety
  • Use of controlled human infection models
  • Need for complete assessment of viremia induced by the vaccine
  • The importance of balanced infectivity in live attenuated vaccines and balanced efficacy across age groups and sero-status
  • Surveillance:
    • Need for improved surveillance systems where dengue vaccine is introduced
    • How long should active surveillance continue?
    • Collection of blood samples – baseline & routinely scheduled collections
Scott Halstead, Adjunct Professor, Department Of Preventive Medicine And Biometrics, Uniformed Services University Of The Health Sciences
Stephen Thomas, Chief, Division Of Infectious Diseases, New York Upstate Medical University
Dr Anna Durbin, Associate Professor, Johns Hopkins Bloomberg School of Public Health
Apr 814:40
Conference pass

Can we achieve global harmonization of regulatory requirements for vaccines to improve time and cost

Supply & Logistics
  • Variability of assays and tests required internationally
  • Practicalities are very challenging
  • Can regulatory bodies work together to achieve harmonization of requirements?
Apr 814:55
Conference pass

Advancements towards first commercial Chikungunya vaccine

Emerging and Infectious
Dr Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience
Apr 814:55
Conference pass

Success case study 2 - Partnering with a non-profit for the first toxoid based multivalent vaccine for MRSA

Partnerships
M Javad Aman, Chief Executive Officer, Integrated Biotherapeutics
Nadia Cohen, Alliance Manager, CARB-X
Apr 815:10
Conference pass

The potential use of human in vitro models to help build better vaccines

Immune Profiling
David Dowling, Instructor In Pediatrics, Boston Children's Hospital
Apr 815:10
Conference pass

The long road to a universal influenza virus vaccine: Research advancements

Respiratory
Dr Peter Palese, Professor And Chair Microbiology, Mount Sinai School of Medicine
Apr 815:10
Conference pass

Successful project delivery through laboratory and clinical integration

Clinical Development
Jason Berg, Director, Project Management, PPD
Apr 815:10
Conference pass

Overview and regulatory issue updates on veterinary biologics in the US and abroad

Veterinary
Will Mccauley, Director, Animal Health Institute
Apr 815:25
Conference pass

Sci-B-Vac: results on Ph3 Hep B vaccine

Emerging and Infectious
Dr Francisco Diaz-Mitoma, Chief Medical Officer, VBI Vaccines
Apr 815:40
Conference pass

Panel: Platforms to inform next generation vaccines – how do we accelerate and de-risk vaccine development?

Immune Profiling
  • Exploring immune profiling platforms to accelerate and de-risk vaccine development
  • Can modelling immune responses outside the body human help to do this?
Duccio Medini, Senior Director, Head Of Data Science And Clinical Systems, GlaxoSmithKline
Apr 815:40
Conference pass

Universal flu challenge models and correlates of protection

Respiratory
Dr Matthew Memoli, Director, NIAID-NIH
Apr 815:40
Conference pass

Current State of CMV Vaccine Development

Emerging and Infectious
Stanley Plotkin, Emeritus Professor, University of Pennsylvania School Of Medicine
Apr 815:40
Conference pass

Next generation delivery systems for veterinary vaccines

Veterinary
Arvind Kumar, Lead, Discovery Biology Research (Bacteriology And Parasitology) Erl, Elanco Animal Health
Apr 815:40
Conference pass

Success case study 3 - Meeting DoD’s vaccine and medical countermeasure development through public-private partnerships

Partnerships
Mike Stebbins, Mcdc Executive Director, Advanced Technology International
Apr 815:55
Conference pass

Site’s perspective on frequent issues around vaccine trials

Clinical Development
William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC
Apr 816:40
Conference pass

Single cell functionality serves as a predictive biomarker for overall survival of pancreatic cancer patients treated with GVAX vaccine

Immune Profiling
Will Singleterry, Director Of Business Development, IsoPlexis
Apr 816:40
Conference pass

Panel: 2020-2030 insights and expectations for the next decade of cancer vaccine development

Cancer & Immunotherapy
  • Session goals: Dr Karolina Palucka, The Jackson Laboratory
  • 4:40 – 5:40: Antigens and adjuvants
  • 5:40 – 6.10: Clinical settings
Madhav Dhodapkar, Professor, Emory University
Jacques Banchereau, Professor, Jackson Laboratory
Joshua Brody, Assistant Professor, Medicine, Hematology And Medical Oncology, Icahn School of Medicine at Mount Sinai
Carl G Figdor, Professor, RadboudUMC
Apr 816:40
Conference pass

Universal flu - Title TBC

Respiratory
Joseph Eiden, Senior Medical Advisor, FluGen Inc
Apr 816:40
Conference pass

A novel vaccine for monkeypox – current status and outlook

Emerging and Infectious
Heinz Weidenthaler, VP Clinical Strategy Infectious Diseases, Bavarian Nordic
Apr 816:40
Conference pass

Strategy for conducting international vaccine clinical trials for infants and toddlers

Clinical Development
  • Using insight/data from pneumococcal and meningococcal A vaccines
Mark Alderson, Director - Pneumococcal Vaccine Project Vaccine Development Global Program, Path
Apr 816:40
Conference pass

Considerations for the process development and cGMP manufacturing of vaccines

Bioprocess & Manufacture
Apr 816:40
Conference pass

Overcoming manufacturing challenges in the veterinary vaccine industry

Veterinary
  • Designing and commissioning high throughput manufacturing facilities
  • Facility and equipment design suitable for campaign production
  • Use of appropriate disposable technologies
  • Improving antigen yield through process optimization
Apr 816:40
Conference pass

Post-marketing assessment of vaccine safety in pregnancy

Vaccine Safety
  • Key issues surrounding post-marketing safety surveillance for vaccines used during pregnancy
  • Update on changes in recently published Post-approval Pregnancy Safety Studies
Steven Anderson, Director, Office of Biostatistics and Epidemiology, U.S. Food and Drug Administration (FDA)
Apr 816:45
Conference pass

Vaccitech – universal vaccine

Respiratory
Thomas Evans, Chief Executive Officer, Vaccitech
Apr 816:55
Conference pass

Modernization of the influenza vaccine

Bioprocess & Manufacture
Daniel Henderson, Chief Executive Officer, Verndari
Apr 817:10
Conference pass

Expeditionary research in emerging & re-emerging disease – session title TBC

Emerging and Infectious
Jason Ezzelle, Chief Commercial And Government Contracts Officer, Pharm-Olam
Apr 817:10
Conference pass

Willingness to participate in vaccine-related clinical trials among older

Clinical Development
Nadine Rouphael, Associate Professor Of Medicine, Emory University
Apr 817:10
Conference pass

Panel: How do you meet the demand of low-cost manufacturing using new vaccine modalities?

Veterinary
Mark Emalfarb, President and Chief Executive Officer, Dyadic International Inc
Apr 817:10
Conference pass

Collaborating with external organisations: create strategic partnerships with big pharmaceutical companies

Partnerships
Philippe Denoel, Director Of External Research And Development, Innovation, Scientific Affairs And Opportunities Collaborations For Public Fundin, GSK Vaccines
Vanitha Sekar, Executive Director, Merck
Apr 817:10
Conference pass

Vaccine safety surveillance: what can we do to improve surveillance studies and databases?

Vaccine Safety
  • Evaluating vaccine safety in children and other at-risk populations
    • E.g. RSV and Pertussis, Live attenuated vs subunit
  • What are the benefits of RCTs and large databases and how can they be improved?
  • How can we ensure we are taking all parameters into account e.g. what time of year is the vaccine given?
  • How do we decide which signals are meaningful?
  • Do we need to revisit the influenza & narcolepsy issue?
  • The need for better databases in LMICs – how do you recognize safety signals? How can they be implemented?
Apr 817:40
Conference pass

Developing high throughput experimental and analytical tools to evaluate the antibody response in infectious disease

Immune Profiling
Margaret Ellen Ackerman, Associate Engineering Professor, Dartmouth College
Apr 817:40
Conference pass

How vaccine delivery solutions impact the efficiency of vaccine campaigns

Respiratory
Apr 817:40
Conference pass

The Delivery Board: Reviewing presentations and their effectiveness

Bioprocess & Manufacture
  • How does different routes of delivery influence the immunological outcome?
  • Effectiveness and usability

Create your personal agenda –check the favourite icon

Apr 909:00
Conference pass

Chair’s opening remarks

Clinical Development
Apr 909:00
Conference pass

Chair's opening remarks

Veterinary
Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Apr 909:10
Conference pass

Machine learning and biomarker discovery for understanding vaccine mode of action

Immune Profiling
Robert Van Den Berg, Director, GlaxoSmithKline Vaccines
Apr 909:10
Conference pass

The importance of therapeutic cancer vaccination for EBV-positive malignancies

Cancer & Immunotherapy
  • EBV-positive cancers are richly infiltrated with diverse immune cells
  • Performing high dimensional phenotyping of EBV tumours
  • Exploring the antigen-specificity of infiltrating T-cells
  • How these results inform the development of therapeutic vaccine strategies
Apr 909:10
Conference pass

The impact of a universal influenza vaccine

Respiratory
Meagan Fitzpatrick, Assistant Professor Of The Center For Vaccine Development And Global Health, University of Maryland
Apr 909:10
Conference pass

Why is an HIV vaccine needed?

Clinical Development
  • Why is it taking so long to develop a vaccine
  • Update on current antiviral and bnAb pipeline
Rama Rao Amara, Professor, Emory University
Kathryn Stephenson, Assistant Medicine Professor, Harvard Medical School
Carl Dieffenbach, Director, Division Of Aids, Niaid, NIH
Apr 909:10
Conference pass

Manufacturing technology showcase: Development of a new manufacturing platform technology for human vaccines

Bioprocess & Manufacture
Dr Andreas Neubert, Vice President Vaccines, IDT Biologika
Dr Andreas Neubert, Vice President Vaccines, IDT Biologika
Apr 909:10
Conference pass

Developing next-generation antibiotic alternatives for animals

Veterinary
Hyun Lillehoj, Animal Biosciences and Biotechnology Laboratory, Agricultural Research Service U.S.D.A.
Apr 909:10
Conference pass

The Safety Platform for Emergency Vaccines (SPEAC) Project

Vaccine Safety
  • The Brighton Collaboration was created in 2000 with the goal of building trust in the safety of vaccines via rigorous science.
  • The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration launched the Safety Platform for Emergency vACcines (SPEAC) Project on May 28, 2020.
  • SPEAC aims to support the emerging CEPI portfolio by creating practical solutions for harmonized safety assessment of CEPI vaccines by working:
    • To enhance vaccine safety assessment across CEPI development programs.
    • To harmonize vaccine safety monitoring during CEPI preclinical and clinical trials.
    • To provide a continuous improvement framework for the SPEAC program.
Apr 909:10
Conference pass

Overcoming barriers to higher vaccination coverage using mobile technology

Supply & Logistics
Katriel Friedman, CEO, Charity Science Health
Apr 909:40
Conference pass

Targeting CMV for the development of effective GBM and MB immunotherapies

Cancer & Immunotherapy
Apr 909:40
Conference pass

Human Challenge with Bordetella pertussis – Recent developments and implications for vaccine research

Respiratory
Prof Robert Read, Head Of Academic Unit - Clinical And Experimental Sciences, Professor Of Infectious Diseases, Honorary Consultant Physician, University of Southampton
Apr 909:40
Conference pass

Manufacturing technology showcase

Bioprocess & Manufacture
Practical solutions enabling rapid and sustainable production
Apr 909:40
Conference pass

IgG-like antibodies as an alternative to antibiotics

Veterinary
Peter Heegaard, Professor, National Veterinary Institute Technical University of Denmark
Apr 909:40
Conference pass

WHO Global Advisory Committee on Vaccine Safety – future challenges for worldwide vaccine safety

Vaccine Safety
Apr 910:10
Conference pass

Versamune plus a multi-epitopic mix of 6 different HPV16 E6 and E7 peptides designed to treat HPV-associated pre-cancers and cancers

Cancer & Immunotherapy
Apr 910:10
Conference pass

Norovirus vaccine development

Emerging and Infectious
Dr Sean Tucker, Chief Scientific Officer And Vice President Research, Vaxart
Apr 910:10
Conference pass

Manufacturing technology showcase: Scalable in vitro manufacturing of tailored vaccines

Bioprocess & Manufacture
Dr Alexander Koglin, Founder, NTx
Apr 910:10
Conference pass

Vaccines as alternatives to antibiotics for food producing animals

Veterinary
Dr Karin Hoelzer, Senior Officer, The Pew Charitable Trusts
Apr 910:10
Conference pass

Crushing the burden of infectious diseases with the use of vaccines

Partnerships
Hayato Urabe, Senior Director, Investment Strategy, Planning and Management, Global Health Innovative Technology Fund
Apr 910:10
Conference pass

Post-marketing safety considerations for a new vaccine developed exclusively for LMIC

Vaccine Safety
  • How to address post-marketing considerations in a region with diverse pharmacovigilance capabilities.
  • The interaction of national stakeholder and manufacturers to overcome challenges to collect safety information in post-marketing?
Apr 911:30
Conference pass

DNA Vaccines to combat a broad range of viral associated cancers

Cancer & Immunotherapy
Amit Adhikari, Scientist, Immunomic Therapeutics
Apr 911:30
Conference pass

Influenza vaccines immunological assessment

Respiratory
Emanuele Montomoli, Professor In Public Health University Of Siena And Chief Scientific Officer, VisMederi
Apr 911:30
Conference pass

Development of a CMV-based HIV vaccine in rhesus monkeys

Clinical Development
Louis Picker, Professor, Oregon Health & Science University
Apr 911:30
Conference pass

Reducing the use of antimicrobials through innovative universal subunit vaccine platform design

Veterinary
Sherry Layton, Cso, Vetanco Sa
Apr 911:30
Conference pass

Financing vaccine development in the Middle East

Partnerships
Dr Turki Almugaiteeb, Chief Technical Officer, RPDC Innovations
Apr 911:30
Conference pass

The Ebola vaccine story; where are we now?

Vaccine Safety
  • Wrapping up the DRC outbreak
  • The licensure process and unique pathway to regulatory approval
  • Policy & ethical considerations
  • Innovations, challenges and lessons learned throughout development
  • Implications for development of future emerging /re-emerging disease vaccines
Dr Beth Ann Griswold-Coller, Executive Director, Vaccines Clinical Research,, Merck Research Laboratories
Apr 911:30
Conference pass

Panel: How can industry work with vaccine non-profits to improve last mile delivery?

Supply & Logistics
  • What are the main challenges faced?
  • What should industry consider to better suit our needs?
    • Temperature stable vaccines, other considerations for products on the market
  • Case studies of what works / doesn’t work for current products
Apr 911:45
Conference pass

Microprojection array patch clinical study with influenza vaccine: Demonstration of efficacy, dose reduction, and high temperature stability – title TBC

Respiratory
Tom Lake, Senior Vice President, Vaccine Development Alliances, Vaxxas
Apr 912:00
Conference pass

Late stage development of a novel DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV)

Cancer & Immunotherapy
Apr 912:00
Conference pass

Protecting the immune system in poultry – role of vaccination

Veterinary
Dr Stéphane Lemiere, Global Avian Technical Director, Boehringer-Ingelheim
Apr 912:00
Conference pass

Investing on late stage projects to contribute towards global health

Partnerships
Apr 913:30
Conference pass

Chair's opening remarks

Keynotes
Gregory Poland, Director Of Mayo Vaccine Research Group, Mayo Clinic
Apr 913:40
Conference pass

How can we keep vaccines development and delivery sustainable for global health and prioritize equity?

Keynotes
  • Sustainable models for vaccine development for LMICs
  • How to approach infectious diseases, outbreaks and AMR pathogens that require considerable investment
  • Are close collaborations between public and private sectors the answer?
An Vermeersch, Vice President And Head Of Global Governmental Affairs And Global Health, GlaxoSmithKline
Apr 914:40
Conference pass

Vaccine hesitancy, measles and policy

Keynotes
  • Have we lost ground?
  • Is elimination still viable?
  • Addressing the driving factors causing lower immunizations rates and outbreaks
Moderator: Thomas Breuer, Senior Vice President, Chief Medical Officer, GSK Vaccines
Paul Offit, Physician, Childrens Hospital of Pennsylvania
Dr Bruce Gellin, President, Global Immunization, Sabin Vaccine Institute
Stanley Plotkin, Emeritus Professor, University of Pennsylvania School Of Medicine
Dr Peter Hotez, Dean, National School Of Tropical Medicine, Director, Texas Children?S Hospital Center, Baylor College of Medicine
last published: 17/Jan/20 10:45 GMT